October 21, 2019 08:55 AM EDT

AstraZeneca's Farxiga scores FDA nod to cut risk of hospitalization for heart failure in diabetics

Natalie Grover

Reporter

While the FDA recently spurned an application to allow AstraZeneca’s blockbuster drug Farxiga for type 1 diabetes that cannot be controlled by insulin, citing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's Farxiga scores FDA nod to cut risk of hospitalization for heart failure in diabetics

Natalie Grover

Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

As­traZeneca's Farx­i­ga scores FDA nod to cut risk of hos­pi­tal­iza­tion for heart fail­ure in di­a­bet­ics

Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

AstraZeneca's Farxiga scores FDA nod to cut risk of hospitalization for heart failure in diabetics